Pharma major Lupin has said that it has launched Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin's Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation's Tobis 300 mg/5 ml.
It is indicated for the management of cystic fibrosis patients with P. aeruginosa. Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Meanwhile, shares of the company were trading at Rs 875.95 apiece up 0.73 per cent from the previous close at 09:25 hrs on BSE.